Grifols SA PRF PERPETUAL EUR 0.05 - Cls B GRFPe
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 27.77
- Price/Sales
- 0.68
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
|
Metric
|
GRFPe
|
4502
|
CSL
|
|---|---|---|---|
Price/Earnings (Normalized) | 27.77 | 15.69 | 29.83 |
Price/Book Value | 0.77 | 0.89 | 5.54 |
Price/Sales | 0.68 | 1.54 | 6.63 |
Price/Cash Flow | 7.76 | 7.51 | 34.62 |
Price/Earnings
GRFPe
4502
CSL
Financial Strength
|
Metric
|
GRFPe
|
4502
|
CSL
|
|---|---|---|---|
Quick Ratio | 0.63 | 0.46 | 0.95 |
Current Ratio | 2.79 | 1.06 | 2.15 |
Interest Coverage | 1.31 | 1.93 | 7.21 |
Quick Ratio
GRFPe
4502
CSL
Profitability
|
Metric
|
GRFPe
|
4502
|
CSL
|
|---|---|---|---|
Return on Assets (Normalized) | 1.30% | 2.86% | 8.11% |
Return on Equity (Normalized) | 4.69% | 6.13% | 18.17% |
Return on Invested Capital (Normalized) | 3.45% | 4.78% | 10.94% |
Return on Assets
GRFPe
4502
CSL
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Bphvwzjdm | Xbrm | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Xcgpvsyf | Fxv | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Ysnppcwq | Pmkh | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Lrzytwzsx | Mvdps | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Qpfcxnkjkc | Krxmy | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Tngmkyrkj | Cdqg | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Cwdtybv | Cqbw | $216.8 Bil | |||
| Amgen Inc
AMGN
| Hxdqcfqgq | Lrdv | $160.2 Bil | |||
| Pfizer Inc
PFE
| Ltdnqcyzt | Kxxwj | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Sqztzjrwv | Wntnz | $116.1 Bil |